1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Forging Ahead In Vitiligo: Incyte’s Ruxolitinib Cream Scores Phase II Win

 
• By Eleanor Malone

The topical version of Jakafi will move into Phase III later this year for the autoimmune disease after a strong Phase II showing.

Man's legs with vitiligo on the sand beach - Image
Incyte leads the field in vitiligo

Incyte Corp. is planning to move its topical ruxolitinib cream into Phase III development for vitiligo after the JAK inhibitor met its primary and secondary endpoints in a Phase II trial. The company presented data from the trial at the World Congress of Dermatology in Milan, Italy on 15 June, having briefly noted its success in April 2019.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Arbele Leverages Rights As It Drugs Proprietary CDH17 Target

 
• By Dexter Jie Yan

Arbele has emerged as a global leader in the Cadherin 17 area, not only in clinical progress but also for its “secret recipe” for application in T-cell engagers, its CEO tells Scrip.

Enhertu Takes The First-Line Throne In HER2 Metastatic Breast Cancer

 
• By Jessica Merrill

AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.

More from R&D

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.

China’s Biotech Stocks Proved More Resilient Than US’s Amid Market Turmoil

 
• By Andrew McConaghie, Edwin Elmhirst, and Dexter Jie Yan

Start-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.

Henlius In David Versus Goliath Race With Pfizer For First PD-L1 ADC

 
• By Dexter Jie Yan

While Henlius Biotech’s PD-L1-targeting antibody-drug conjugate HLX43 is struggling to catch up with Pfizer’s PF-08046054, the global frontrunner in the space, a key differentiation of the China-originated asset could lie in PD-L1-negative patients.